AlphAIalphai — Financial news for AI agents
fool.comAUG 193 min read$ICCM

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.

Original reporting
fool.com
Published Aug 19, 2026, 4:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$ICCMNeutralMed
01

Why it matters

The earnings call provides the first public disclosure of H1 2026 financials and a new financing round, offering fresh data for valuation.

02

Market read

Provides new earnings data and financing details for a niche biotech, affecting short‑term price expectations.

03

What to watch

Potential regulatory approvals in Japan and new CPT codes could materially improve future revenue.

Relevance 7/10Novelty 7/10Timing: post‑earnings H1 2026 release

Background

IceCure Medical is a small‑cap medical device company focusing on cryoablation systems for tumor treatment.

Company-level read

Ticker impact

$ICCMNeutralMedium confidence
Context

IceCure Medical reported H1 2026 revenue of $1.8M, a 45% increase, and disclosed a $8.5M financing round and cash balance of $12M.

Expected impact

Potential modest upside if financing supports commercial expansion; downside risk from cash‑burn and going‑concern doubts.

Evidence & confidence

Positive revenue trends offset by significant net loss and limited cash for next 12 months.

Market effects

Sector

Highlights growth potential in cryoablation oncology devices and may influence peer valuations.

Regional

U.S. market sees increased interest; European investors watch foreign exchange impact.

Global

Limited to niche medical device sector.

Counterpoint

What could challenge this read

Cash runway concerns could trigger a sell‑off despite revenue growth.

Key entities

  • Company
    IceCure Medical Ltd

    Issuer of the earnings call.

  • Clinical Trial
    CHOICE Study

    Post‑market study driving future commercial adoption.

Read at source← All news

Related articles

AUG 20
$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

prnewswire.com2 min
AUG 13
$ICCMMed

IceCure Reports First Half Of 2026 Results With Strong Revenue Growth

IceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.

rttnews.com4 min
AUG 12
$ICCMMed

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.

yahoo.com7 min
JUN 17
$ICCMMedAI 8/10

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

IceCure Medical (NASDAQ: ICCM) said its U.S. active commercial install base for its ProSense breast cancer cryoablation system rose 70% after FDA marketing authorization in October 2025. The company attributed growth to expanding physician demand, clinical guideline support (ASBrS resource guide), and increased patient awareness, including Reuters and local TV coverage.

prnewswire.com3 min